At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
BMS-986315 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating BMS-986315, nivolumab, and 1 other intervention for Advanced Solid Tumor. Completed, enrolled 44 participants across 8 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesCanada, Mexico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartJul 2020
Primary CompletionAug 2024
TodayJul 2026
First PostedApr 16, 2020
Enrollment StartJul 14, 2020
Primary CompletionAug 22, 2024
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 6.2 years ago
Interventions
BMS-986315biological
Specified dose on specified days
nivolumabbiological
Specified dose on specified days
cetuximabbiological
Specified dose on specified days